Physician profile
Daniel L Spitz
NPI 1134125214
$26,541.24
in general payments reported to CMS, 2019-2025
99 companies · $5,599 in 2025
The $5,599 reported for 2025 was more than what 75% of Medical Oncology providers received nationally (typical 2025 total: $1,158).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $2,849 · 2020: $1,974 · 2021: $2,138 · 2022: $3,556 · 2023: $4,506 · 2024: $5,921 · 2025: $5,599.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $15K · Education: $548 · Long Term Medical Supply Or Device Loan: $299.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $15,178.84 |
| Education | $547.56 |
| Long Term Medical Supply Or Device Loan | $299.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $2,927.34 | 2019-2025 | Tecvayli, Darzalex, Rybrevant |
| Novartis Pharmaceuticals Corporation | $2,058.45 | 2019-2025 | Kisqali, Piqray |
| Pfizer INC. | $1,656.31 | 2019-2025 | |
| Celgene Corporation | $1,441.81 | 2019-2025 | Reblozyl, Pomalyst, Opdualag |
| Astrazeneca Pharmaceuticals LP | $1,425.30 | 2019-2025 | Lynparza, Enhertu, Tagrisso |
| Incyte Corporation | $1,093.47 | 2019-2025 | Jakafi, Monjuvi, Zynyz |
| Seagen INC. | $927.92 | 2019-2023 | Tivdak, Tukysa, Padcev |
| Eisai INC. | $868.64 | 2019-2025 | |
| Glaxosmithkline, LLC. | $861.96 | 2020-2025 | Zejula, Jemperli, Ojjaara |
| Merck Sharp & Dohme LLC | $859.82 | 2019-2025 | Keytruda, Lynparza, Reblozyl |
| E.R. Squibb & Sons, L.L.C. | $773.59 | 2019-2025 | Opdivo, Opdualag, Krazati |
| Genentech USA, INC. | $733.91 | 2019-2025 | Tecentriq, Phesgo, Itovebi |
| Genzyme Corporation | $719.62 | 2019-2025 | |
| Lilly USA, LLC | $686.13 | 2019-2025 | Jaypirca, Verzenio, Retevmo |
| Daiichi Sankyo INC. | $545.31 | 2020-2025 | Enhertu, Datroway |
Show all 94 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $469.25 | 2019-2023 | Kyprolis |
| Bayer Healthcare Pharmaceuticals INC. | $468.25 | 2019-2025 | |
| Astellas Pharma US INC | $443.33 | 2019-2025 | Xtandi, Vyloy, Xospata |
| Abbvie INC. | $427.91 | 2019-2025 | Venclexta |
| Sobi, INC | $396.66 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $389.11 | 2019-2025 | Vonvendi, Vpriv, Alunbrig |
| Pharmacyclics LLC, An Abbvie Company | $294.08 | 2019-2023 | Imbruvica, Epkinly |
| Jazz Pharmaceuticals INC. | $290.82 | 2019-2025 | |
| Rigel Pharmaceuticals, INC. | $284.25 | 2023-2025 | Rezlidhia, Tavalisse, Tavalisse |
| Boehringer Ingelheim Pharmaceuticals, INC. | $249.98 | 2019-2025 | |
| Ipsen Biopharmaceuticals, INC | $248.83 | 2019-2024 | Onivyde, Tazverik, Somatuline Depot |
| Beigene USA, INC. | $245.62 | 2023-2025 | Brukinsa, Tevimbra |
| Alexion Pharmaceuticals, INC. | $240.27 | 2021-2025 | Ultomiris |
| Blueprint Medicines Corporation | $237.62 | 2020-2025 | Ayvakit |
| Tersera Therapeutics LLC | $218.61 | 2023-2025 | Zoladex |
| Regeneron Healthcare Solutions, INC. | $203.74 | 2019-2024 | Libtayo |
| Kite Pharma, INC. | $199.08 | 2020-2025 | Yescarta |
| Adc Therapeutics America, INC. | $160.95 | 2024-2025 | |
| Emd Serono, INC. | $154.48 | 2020-2025 | Bavencio |
| Adaptive Biotechnologies Corporation | $146.94 | 2022-2024 | Clonoseq |
| Puma Biotechnology, INC. | $129.97 | 2019-2025 | |
| Karyopharm Therapeutics INC. | $127.13 | 2021-2025 | Xpovio |
| Exelixis INC. | $126.40 | 2019-2025 | Cabometyx |
| Stemline Therapeutics INC. | $119.16 | 2025 | Orserdu |
| Aurobindo Pharma USA, INC. | $118.15 | 2019-2020 | |
| Array Biopharma INC | $116.34 | 2020-2025 | Braftovi, Mektovi, Lorbrena |
| Pharmacosmos Therapeutics INC. | $109.57 | 2023-2025 | Monoferric, Cosela |
| Agios Pharmaceuticals, INC. | $106.54 | 2020-2025 | Pyrukynd |
| Clovis Oncology, INC. | $102.04 | 2019-2021 | |
| Menarini Silicon Biosystems, INC. | $97.50 | 2024 | |
| Kyowa Kirin, INC. | $94.34 | 2023-2025 | Poteligeo |
| Dova Pharmaceuticals | $91.66 | 2019-2021 | |
| Tempus Ai, INC | $90.66 | 2024 | Xt Cdx |
| Dendreon Pharmaceuticals LLC | $89.62 | 2021-2025 | Provenge |
| Legend Biotech USA INC. | $84.50 | 2024-2025 | Carvykti |
| Taiho Oncology, INC. | $83.11 | 2021-2025 | |
| Deciphera Pharmaceuticals INC. | $79.23 | 2024-2025 | Qinlock, Romvimza |
| Gilead Sciences, INC. | $78.59 | 2021-2024 | |
| Pharmaessentia USA Corporation | $72.96 | 2022-2025 | Besremi |
| Napo Pharmaceuticals INC | $70.99 | 2024 | Gelclair Concentrated Oral Gel |
| Sirtex Medical INC | $63.62 | 2020-2022 | |
| Geron Corporation | $60.30 | 2025 | Rytelo |
| Springworks Therapeutics, INC. | $58.04 | 2025 | Ogsiveo |
| Recordati_rare_diseases_inc. | $49.94 | 2024 | Sylvant |
| Beone Medicines USA, INC. | $46.05 | 2025 | Tevimbra, Brukinsa |
| Aveo Pharmaceuticals, INC. | $44.95 | 2021-2022 | |
| Emmaus Medical, INC. | $43.24 | 2020-2022 | |
| Foundation Medicine, INC. | $43.08 | 2019 | |
| Advanced Accelerator Applications | $41.94 | 2019-2020 | |
| Octapharma USA, INC. | $39.87 | 2020-2022 | |
| Alnylam Pharmaceuticals INC. | $39.46 | 2024 | Onpattro |
| G1 Therapeutics, INC. | $38.68 | 2022 | |
| Ge Healthcare | $38.33 | 2025 | |
| Morphosys, US INC. | $38.24 | 2021 | |
| Shield Therapeutics INC | $36.85 | 2023-2024 | Accrufer |
| Cumberland Pharmaceuticals, INC. | $35.43 | 2023 | Sancuso |
| Medtronic, INC. | $31.88 | 2022 | |
| Myriad Genetic Laboratories, INC. | $31.04 | 2021 | |
| Accord Healthcare, INC. | $30.49 | 2025 | |
| Secura Bio, INC. | $29.65 | 2019-2020 | |
| Immunocore Limited | $28.39 | 2025 | Kimmtrak |
| Genmab U.S., INC. | $25.54 | 2024 | Epkinly |
| Heron Therapeutics, INC. | $25.15 | 2022 | |
| Janssen Scientific Affairs, LLC | $24.96 | 2019 | |
| Nuvation Bio INC. | $22.24 | 2025 | Ibtrozi |
| Servier Pharmaceuticals LLC | $21.93 | 2022 | |
| Janssen Pharmaceuticals, INC | $21.41 | 2023-2024 | Xarelto |
| Shire North American Group INC | $21.31 | 2019 | |
| Amneal Pharmaceuticals LLC | $21.31 | 2023 | Neupogen, Avastin, Neulasta |
| Delcath Systems | $21.26 | 2025 | Hepzato Kit |
| Partner Therapeutics, INC. | $20.09 | 2020 | |
| Spectrum Pharmaceuticals INC. | $19.67 | 2023 | Rolvedon |
| Biocon Biologics INC | $19.44 | 2025 | Ogivri |
| Verastem, INC. | $18.70 | 2019 | |
| Tg Therapeutics, INC. | $17.14 | 2021 | |
| Global Blood Therapeutics, INC. | $13.64 | 2021 | |
| Innate Pharma, INC | $13.54 | 2020 | |
| Pharmaand Gmbh | $4.86 | 2025 | Rubraca |
| Veracyte, INC. | $1.76 | 2020 |
5 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$31,787.18 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Spitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.